statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday...

Corvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)

Mizuho restated their neutral rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. Mizuho currently...

Corvus Pharmaceuticals (NASDAQ:CRVS) Rating Reiterated by Mizuho

Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Corvus Pharmaceuticals (CRVS Research Report) on March 26 and set a price...

Hold Rating Maintained for Corvus Pharmaceuticals Amid Clinical Delays and Financing Concerns

Corvus Pharmaceuticals (NASDAQ:CRVS  Get Free Report)s stock had its neutral rating restated by equities research analysts at Mizuho in a research report issued to clients...

Mizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)

Figure 1

 Waterfall Plot for Patients in the 200 mg Dose Cohort of the Soquelitinib Phase 1/1b Clinical Trial for Peripheral T Cell Lymphoma. The plot shows the best percent change in...

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PTBURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage...

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

Anebulo Pharmaceuticals (NASDAQ:ANEB  Get Free Report) and Corvus Pharmaceuticals (NASDAQ:CRVS  Get Free Report) are both small-cap medical companies, but which is the superior...

Comparing Corvus Pharmaceuticals (NASDAQ:CRVS) & Anebulo Pharmaceuticals (NASDAQ:ANEB)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS  Get Free Report) was the recipient of a large decrease in short interest during the month of February. As of February 15th, there was short interest...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in February

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Corvus Pharmaceuticals presents preclinical data for soquelitinib

Poster presentation unveils Corvus' next-generation ITK inhibitor candidates designed to deliver precise T cell modulation for immunology indications
 Figure 1

 Venn diagram...

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

Watchers	5,776
52-Wk Low	$1.05
52-Wk High	$4.19

Volume	1.05M
52-Wk High	$4.19
52-Wk Low	$1.05

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.14	--	--	N/A
Q1'24	-$0.14	-$0.12	11.11%	BEAT
Q4'23	-$0.12	-$0.14	-16.67%	MISSED
Q3'23	-$0.12	-$0.12	2.04%	BEAT
Q2'23	-$0.14	-$0.14	--	EXPECTED

CRVS Corvus Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals